. 2017 Sep 21;7(1):e1372081. doi: 10.1080/2162402X.2017.1372081

Table 1b.

Relapsed patients (A-D from Table 1a).

Patient	Time of relapse	Site(s) of relapse	Treatment	Treatment duration	Response	RFS from start of treatment^* (months)	RFS from end of treatment^* (months)
A	1 mo after last vaccine	Lung, spleen	Ipilimumab + nivolumab	14 months	CR	44	30
A	8.3 mo from resection	Lung, spleen	Ipilimumab + nivolumab	14 months	CR	44	30
B	1 mo after last vaccine	Liver, spleen	Ipilimumab + nivolumab	4 months	CR	43	39.3
B	7.4 mo from resection	Liver, spleen	Ipilimumab + nivolumab	4 months	CR	43	39.3
C	1 mo after last vaccine	Bone	Multiple including ipilimumab & pembrolizumab	16 months total	POD	NA	NA
C	5.2 mo from resection	Bone	Multiple including ipilimumab & pembrolizumab	16 months total	POD	NA	NA
D	On study after 3rd vaccine	Skin, CNS	Lirilumab + nivolumab	One dose	CR	40.2	40.2
D	4 mo from resection	Skin, CNS	Lirilumab + nivolumab	One dose	CR	40.2	40.2

CR = complete response; EOS = end of study; F/u = follow-up; NA = not applicable; NED = no evidence of disease; POD = progression of disease; RFS = recurrence-free survival

cutoff date 07/01/2017, approximately 31 months from the end of the study